Zhu Li

TL;DR: 5-HT has joined DA as a critical target for developing effective APDs and led to the search for novel drugs with complex pharmacology, ending the exclusive search for single-receptor targets.

TL;DR: It is demonstrated that aripiprazole, at low doses of 0.1 and 0.3 mg/kg, increases dopamine release in the medial prefrontal cortex and hippocampus, and suggests that the function of both the medial amygdala and hippocampus may contribute to the ability of aripIPrazole to improve negative symptom and cognition.

TL;DR: Results indicate that quetiapine, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a 5-HT(1A)-related mechanism, however, 5- HT( 1A) agonism may be important only for quet iapine-induced ACh release.

TL;DR: NDMC, because of its M1 agonism, may more effectively treat the cognitive impairments observed in schizophrenia than clozapine itself; and M1 receptor agonism may be a valuable target for the development of drugs that can improve cognitive deficit in schizophrenia, and perhaps other neuropsychiatric disorders as well.

TL;DR: Clozapine increases ACh and DA release in the vHIP and mPFC, whereas haloperidol has minimal effects on the release of these two neurotransmitters in either region, suggesting the role of hippocampus in the cognitive effects of atypical APDs warrants more intensive study.